1/7
08:10 am
uthr
ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors [Yahoo! Finance]
Low
Report
ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors [Yahoo! Finance]
1/6
10:05 am
uthr
United Therapeutics (NASDAQ:UTHR) was given a new $645.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Low
Report
United Therapeutics (NASDAQ:UTHR) was given a new $645.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
1/5
07:40 am
uthr
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
07:00 am
uthr
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/24
07:33 am
uthr
S&P 500 Futures Flat in Premarket Trading; United Therapeutics, Intel Lag [Barron's]
Medium
Report
S&P 500 Futures Flat in Premarket Trading; United Therapeutics, Intel Lag [Barron's]
11/26
02:23 pm
uthr
United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
11/21
12:18 pm
uthr
United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base [Yahoo! Finance]
Low
Report
United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base [Yahoo! Finance]
11/20
11:54 pm
uthr
United Therapeutics: Growing Company With Great Franchise In Pulmonary Diseases [Seeking Alpha]
Low
Report
United Therapeutics: Growing Company With Great Franchise In Pulmonary Diseases [Seeking Alpha]
11/20
01:40 pm
uthr
United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
06:02 am
uthr
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/14
01:19 pm
uthr
United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
02:04 pm
uthr
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/10
03:16 am
uthr
3 Reasons Investors Love United Therapeutics (UTHR) [Yahoo! Finance]
Low
Report
3 Reasons Investors Love United Therapeutics (UTHR) [Yahoo! Finance]
11/9
01:13 am
uthr
United Therapeutics (NASDAQ:UTHR) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
United Therapeutics (NASDAQ:UTHR) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
11/6
01:29 pm
uthr
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at UBS Group AG from $580.00 to $600.00. They now have a "buy" rating on the stock.
Low
Report
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at UBS Group AG from $580.00 to $600.00. They now have a "buy" rating on the stock.
11/4
12:39 pm
uthr
First clinical trial of pig kidney transplants gets underway [Los Angeles Times (CA)]
Low
Report
First clinical trial of pig kidney transplants gets underway [Los Angeles Times (CA)]
11/4
07:00 am
uthr
United Therapeutics Corporation to Present at Upcoming Investor Conferences
Low
Report
United Therapeutics Corporation to Present at Upcoming Investor Conferences
11/3
07:00 am
uthr
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Low
Report
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
10/30
06:43 pm
uthr
United Therapeutics (UTHR): Earnings Growth Slows, Reinforcing Cautious Market Narratives Despite High Margins [Yahoo! Finance]
Low
Report
United Therapeutics (UTHR): Earnings Growth Slows, Reinforcing Cautious Market Narratives Despite High Margins [Yahoo! Finance]
10/30
11:04 am
uthr
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/30
11:02 am
uthr
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at Wells Fargo & Company from $414.00 to $423.00. They now have an "equal weight" rating on the stock.
Low
Report
United Therapeutics (NASDAQ:UTHR) had its price target raised by analysts at Wells Fargo & Company from $414.00 to $423.00. They now have an "equal weight" rating on the stock.
10/30
10:59 am
uthr
United Therapeutics (NASDAQ:UTHR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
United Therapeutics (NASDAQ:UTHR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/29
08:11 pm
uthr
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
10/29
03:58 pm
uthr
United Therapeutics (NASDAQ:UTHR) was given a new $447.00 price target on by analysts at Morgan Stanley.
Low
Report
United Therapeutics (NASDAQ:UTHR) was given a new $447.00 price target on by analysts at Morgan Stanley.
10/29
06:30 am
uthr
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
High
Report
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results